Compare · GLP-1 agonist
Mazdutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Semaglutide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that switches on two of the body's metabolic hormone receptors at the same time. Most of the buzzy GLP-1 compounds are still stuck at the press-release stage, but mazdutide is further along: it has a full Phase 3 trial published in…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.